View in EDS

Motor and Non-motor Complications Following Different Early Therapies in Parkinson's Disease: Longitudinal Analysis of Real-Life Clinical and Therapeutic Data from the French NS-PARK Cohort.

Saved in:
Bibliographic Details
Title: Motor and Non-motor Complications Following Different Early Therapies in Parkinson's Disease: Longitudinal Analysis of Real-Life Clinical and Therapeutic Data from the French NS-PARK Cohort.
Authors: Lanore, Aymeric (AUTHOR), Januel, Edouard (AUTHOR), Bertille, Nathalie (AUTHOR), Fabbri, Margherita (AUTHOR), Mariani, Louise-Laure (AUTHOR), Mangone, Graziella (AUTHOR), Sambin, Sara (AUTHOR), Menon, Poornima Jayadev (AUTHOR), Tir, Melissa (AUTHOR), Bereau, Matthieu (AUTHOR), Meissner, Wassilios G. (AUTHOR), Thiriez, Claire (AUTHOR), Marques, Ana (AUTHOR), Remy, Philippe (AUTHOR), Dupont, Gwendoline (AUTHOR), Moro, Elena (AUTHOR), Defebvre, Luc (AUTHOR), Houeto, Jean Luc (AUTHOR), Thobois, Stéphane (AUTHOR), Azulay, Jean-Philippe (AUTHOR)
Source: CNS Drugs. Sep2025, Vol. 39 Issue 9, p879-891. 13p.
Subjects: Parkinson's disease, Dopamine agonists, Movement disorders, Cohort analysis, Dopa, Therapeutics, Neurobehavioral disorders
Geographic Terms: France
Abstract: Background: Levodopa, dopamine agonists (DA) and monoamine oxidase inhibitors (MAOI) are all approved first-line therapies for Parkinson's disease (PD), as monotherapy or in combination. Data on their use in the early management of patients with PD in real-life are lacking. Our objective was to assess the impact of early therapeutic strategies on the development of motor and neuropsychiatric complications using a nationwide PD cohort. Methods: NS-PARK is a cohort of patients with PD recruited between 2011 and 2021 from 26 expert centres for PD in France. We analysed the patients with less than 5-years disease duration and no motor complications at inclusion. We used interval censoring survival models to assess the associations between therapeutic strategies (levodopa monotherapy, levodopa alternative therapies or levodopa combinations) and motor fluctuations, dyskinesia, impulse control and related behaviours (ICRBs), apathy, psychosis/hallucination and daytime sleepiness. Analyses were adjusted for sex, age, disease duration, dopaminergic dose and disease severity. Results: We included 1722 patients (38.4% female, median age 67.7 years). At inclusion, 41% received levodopa monotherapy, 31% received levodopa alternative therapies and 28% received levodopa combinations. Compared with levodopa monotherapy, levodopa alternative therapies were associated with a lower dyskinesia risk (hazard ratio (HR) 0.48, 95% confidence interval (CI)[0.28–0.84]), but there was no significant difference in motor fluctuations. Both levodopa alternative and combinations therapies increased ICRBs risk (HR 4.06, 95% CI [2.48–6.67]; HR 5.16, 95% CI [3.00–8.86]) and decreased apathy risk (HR 0.36, 95% CI [0.26–0.49]; HR 0.52, 95% CI [0.39–0.69]). No association was found with psychosis/hallucination or daytime sleepiness. Conclusions: In this real-life cohort, our data supported an association between levodopa alternative therapies and a lower risk of dyskinesia and apathy, but a higher risk of ICRBs compared with levodopa monotherapy. ClinicalTrials.gov Identifier: NCT04888364. Registered June 2021. [ABSTRACT FROM AUTHOR]
Copyright of CNS Drugs is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
FullText Text:
  Availability: 0
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 187386098
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Motor and Non-motor Complications Following Different Early Therapies in Parkinson's Disease: Longitudinal Analysis of Real-Life Clinical and Therapeutic Data from the French NS-PARK Cohort.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Lanore%2C+Aymeric%22">Lanore, Aymeric</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Januel%2C+Edouard%22">Januel, Edouard</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Bertille%2C+Nathalie%22">Bertille, Nathalie</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Fabbri%2C+Margherita%22">Fabbri, Margherita</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Mariani%2C+Louise-Laure%22">Mariani, Louise-Laure</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Mangone%2C+Graziella%22">Mangone, Graziella</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Sambin%2C+Sara%22">Sambin, Sara</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Menon%2C+Poornima+Jayadev%22">Menon, Poornima Jayadev</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Tir%2C+Melissa%22">Tir, Melissa</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Bereau%2C+Matthieu%22">Bereau, Matthieu</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Meissner%2C+Wassilios+G%2E%22">Meissner, Wassilios G.</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Thiriez%2C+Claire%22">Thiriez, Claire</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Marques%2C+Ana%22">Marques, Ana</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Remy%2C+Philippe%22">Remy, Philippe</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Dupont%2C+Gwendoline%22">Dupont, Gwendoline</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Moro%2C+Elena%22">Moro, Elena</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Defebvre%2C+Luc%22">Defebvre, Luc</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Houeto%2C+Jean+Luc%22">Houeto, Jean Luc</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Thobois%2C+Stéphane%22">Thobois, Stéphane</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Azulay%2C+Jean-Philippe%22">Azulay, Jean-Philippe</searchLink> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22CNS+Drugs%22">CNS Drugs</searchLink>. Sep2025, Vol. 39 Issue 9, p879-891. 13p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Parkinson's+disease%22">Parkinson's disease</searchLink><br /><searchLink fieldCode="DE" term="%22Dopamine+agonists%22">Dopamine agonists</searchLink><br /><searchLink fieldCode="DE" term="%22Movement+disorders%22">Movement disorders</searchLink><br /><searchLink fieldCode="DE" term="%22Cohort+analysis%22">Cohort analysis</searchLink><br /><searchLink fieldCode="DE" term="%22Dopa%22">Dopa</searchLink><br /><searchLink fieldCode="DE" term="%22Therapeutics%22">Therapeutics</searchLink><br /><searchLink fieldCode="DE" term="%22Neurobehavioral+disorders%22">Neurobehavioral disorders</searchLink>
– Name: SubjectGeographic
  Label: Geographic Terms
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22France%22">France</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Background: Levodopa, dopamine agonists (DA) and monoamine oxidase inhibitors (MAOI) are all approved first-line therapies for Parkinson's disease (PD), as monotherapy or in combination. Data on their use in the early management of patients with PD in real-life are lacking. Our objective was to assess the impact of early therapeutic strategies on the development of motor and neuropsychiatric complications using a nationwide PD cohort. Methods: NS-PARK is a cohort of patients with PD recruited between 2011 and 2021 from 26 expert centres for PD in France. We analysed the patients with less than 5-years disease duration and no motor complications at inclusion. We used interval censoring survival models to assess the associations between therapeutic strategies (levodopa monotherapy, levodopa alternative therapies or levodopa combinations) and motor fluctuations, dyskinesia, impulse control and related behaviours (ICRBs), apathy, psychosis/hallucination and daytime sleepiness. Analyses were adjusted for sex, age, disease duration, dopaminergic dose and disease severity. Results: We included 1722 patients (38.4% female, median age 67.7 years). At inclusion, 41% received levodopa monotherapy, 31% received levodopa alternative therapies and 28% received levodopa combinations. Compared with levodopa monotherapy, levodopa alternative therapies were associated with a lower dyskinesia risk (hazard ratio (HR) 0.48, 95% confidence interval (CI)[0.28–0.84]), but there was no significant difference in motor fluctuations. Both levodopa alternative and combinations therapies increased ICRBs risk (HR 4.06, 95% CI [2.48–6.67]; HR 5.16, 95% CI [3.00–8.86]) and decreased apathy risk (HR 0.36, 95% CI [0.26–0.49]; HR 0.52, 95% CI [0.39–0.69]). No association was found with psychosis/hallucination or daytime sleepiness. Conclusions: In this real-life cohort, our data supported an association between levodopa alternative therapies and a lower risk of dyskinesia and apathy, but a higher risk of ICRBs compared with levodopa monotherapy. ClinicalTrials.gov Identifier: NCT04888364. Registered June 2021. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of CNS Drugs is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=187386098
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s40263-025-01193-5
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 13
        StartPage: 879
    Subjects:
      – SubjectFull: Parkinson's disease
        Type: general
      – SubjectFull: Dopamine agonists
        Type: general
      – SubjectFull: Movement disorders
        Type: general
      – SubjectFull: Cohort analysis
        Type: general
      – SubjectFull: Dopa
        Type: general
      – SubjectFull: Therapeutics
        Type: general
      – SubjectFull: Neurobehavioral disorders
        Type: general
      – SubjectFull: France
        Type: general
    Titles:
      – TitleFull: Motor and Non-motor Complications Following Different Early Therapies in Parkinson's Disease: Longitudinal Analysis of Real-Life Clinical and Therapeutic Data from the French NS-PARK Cohort.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Lanore, Aymeric
      – PersonEntity:
          Name:
            NameFull: Januel, Edouard
      – PersonEntity:
          Name:
            NameFull: Bertille, Nathalie
      – PersonEntity:
          Name:
            NameFull: Fabbri, Margherita
      – PersonEntity:
          Name:
            NameFull: Mariani, Louise-Laure
      – PersonEntity:
          Name:
            NameFull: Mangone, Graziella
      – PersonEntity:
          Name:
            NameFull: Sambin, Sara
      – PersonEntity:
          Name:
            NameFull: Menon, Poornima Jayadev
      – PersonEntity:
          Name:
            NameFull: Tir, Melissa
      – PersonEntity:
          Name:
            NameFull: Bereau, Matthieu
      – PersonEntity:
          Name:
            NameFull: Meissner, Wassilios G.
      – PersonEntity:
          Name:
            NameFull: Thiriez, Claire
      – PersonEntity:
          Name:
            NameFull: Marques, Ana
      – PersonEntity:
          Name:
            NameFull: Remy, Philippe
      – PersonEntity:
          Name:
            NameFull: Dupont, Gwendoline
      – PersonEntity:
          Name:
            NameFull: Moro, Elena
      – PersonEntity:
          Name:
            NameFull: Defebvre, Luc
      – PersonEntity:
          Name:
            NameFull: Houeto, Jean Luc
      – PersonEntity:
          Name:
            NameFull: Thobois, Stéphane
      – PersonEntity:
          Name:
            NameFull: Azulay, Jean-Philippe
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 09
              Text: Sep2025
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-print
              Value: 11727047
          Numbering:
            – Type: volume
              Value: 39
            – Type: issue
              Value: 9
          Titles:
            – TitleFull: CNS Drugs
              Type: main
ResultId 1